| Cat.No. | Name | Information |
|---|---|---|
| M6167 | Palbociclib | Palbociclib is a highly specific inhibitor of Cdk4 (IC50=11 nM) and Cdk6 (IC50=16 nM), having no activity against a panel of 36 additional protein kinases. |
| M5305 | RO-3306 | RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases. |
| M5228 | THZ1 | THZ1 is a covalent CDK7 inhibitor which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7. |
| M5206 | Tricin | Tricin is a natural flavonoid that is abundant in rice bran. Tricin inhibits HCMV replication by inhibiting CDK9. Tricin inhibits proliferation and invasion of C6 glioma cells by upregulating faK-targeted microrNA-7 expression. |
| M4889 | Ribociclib succinate (LEE011 succinate) | Ribociclib succinate (LEE011 succinate) is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. |
| M3519 | PHA-848125 | PHA-848125 is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7. |
| M3475 | PHA-793887 | PHA-793887 is a novel and potent inhibitor of CDK2, CDK5 and CDK7 with IC50 of 8 nM, 5 nM and 10 nM. It is greater than 6-fold more selective for CDK2, 5, and 7 than CDK1, 4, and 9. |
| M2112 | LY2835219 mesylate | LY2835219 mesylate is an orally available inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM, respectively. |
| M1974 | Roscovitine (Seliciclib) | Roscovitine is a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. |
| M1807 | SCH727965 (dinaciclib) | SCH727965 (Dinaciclib) is a potent and selective CDK inhibitor with IC50 values of 1, 1, 3 and 4 nM for CDK2, CDK5, CDK1 and CDK9, respectively. |
| M1806 | PD 0332991 HCL | PD-0332991 HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. |
| M1710 | Flavopiridol | Flavopiridol (Alvocidib) is a competitive broad-spectrum CDK inhibitor with IC50 of 30,170,100 nM against CDK1, CDK2 and CDK4, respectively. |
| M1653 | AT7519 | AT7519 is a novel small molecule multi-cyclin-dependent (CDK) kinase inhibitor. |
| M58388 | Abemaciclib metabolites M2 | Abemaciclib metabolite M2 (LSN2839567) is a metabolite of Abemaciclib, acts as a potent CDK4 and CDK6 inhibitor, with IC50 values of 1.2 and 1.3 nM, respectively. |
| M55945 | BLU-222 | BLU-222 is an orally effective and selective CDK2 inhibitor. |
| M54710 | Senexin B | Senexin B is a potent, orally active CDK8/19 inhibitor with Kd values of 140 nM and 80 nM for CDK8 and CDK19, respectively. |
| M54707 | INX-315 | INX-315 is an orally potent and selective CDK2 inhibitor that induces cell cycle arrest in G1 phase. INX-315 also induces CDK2 substrate phosphorylation and inhibits tumor growth in a dose-dependent manner in a xenograft mouse model.INX-315 can be used in cancer-related studies. |
| M45136 | PF-07220060 | PF-07220060 is a potent CDK4/CDK6 inhibitor with Ki values of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3. |
| M38915 | Vanicoside B | Vanicoside B targets cyclin-dependent kinase 8 (CDK8) and exhibits anti-tumor activity. The potential mechanism is Vanicoside B blocks CDK8-mediated signaling pathways and decreases the expression of epithelial-mesenchymal transition proteins, so that it leads to cell cycle arrest and apoptosis. |
| M31200 | CK7 | CK7 is a Cdk2/9 inhibitor, which can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
